A newlywed has become the first NHS patient in England with an aggressive form of leukaemia to have a pioneering treatment developed by UCL researchers. The chimeric antigen receptor (CAR) T-cell therapy – known as ‘obe-cel’ and marketed as Aucatzyl – involves taking a patient’s immune cells and reprogramming them in a lab to identify and target their cancer, before returning them to the body as ‘living medicine’. Obe-cel is a second-generation CAR T cell therapy invented by scientists from the